title: [Hodgkin lymphoma].
abstract: ABVD regimen has been established as a standard therapy for Hodgkin lymphoma, and over 70% of patients with Hodgkin lymphoma would be curable. But some refractory diseases still exist. Recent developments of molecular target agents have been expecting to improve the clinical outcomes of Hodgkin lymphoma. Anti CD30 antibody-drug conjugate, brentuximab vedotin, is a promising drug for relapsed and refractory Hodgkin lymphoma, and is also explored to be incorporated into first line therapy. Small molecules such as HDACIs and mTOR inhibitors have been proved as active agents for relapsed diseases. Standard care of Hodgkin lymphoma could be changed in next decade by these molecular targeting agents.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nagai
mesh_terms: D000079963:Brentuximab Vedotin; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy
chemical_list: D056572:Histone Deacetylase Inhibitors; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin